Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on February 27, 2020, to report the entry into a material definitive agreement. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details a registered direct offering of common stock. Key transaction metrics include:
- Shares Issued: 8,461,540 shares of common stock.
- Price Per Share: $1.30.
- Gross Proceeds: Approximately $11.0 million.
- Closing Date: February 28, 2020.
- Placement Agent: H.C. Wainwright & Co., LLC.
- Agent Fees: 6.5% cash placement fee, 1.0% management fee, $25,000 expense allowance, $12,900 clearing expenses, and $50,000 reimbursement for legal and other accountable expenses.
The filing text does not provide clear values for the company's current revenue, profit, cash flow, operating margins, total debt, or liquidity position outside of the proceeds from this specific offering.
Material Changes Versus Prior Period
This filing reports a discrete capital raising event rather than a comparative financial period. The material change is the increase in share count and cash assets resulting from the issuance of 8,461,540 new shares. No prior comparable period financial data is included in this document.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding the validity of the shares and state securities laws. The transaction was executed pursuant to a shelf registration statement (Form S-3) effective since October 10, 2017.
Investor Verification Checklist
- Verify the dilution impact of the 8,461,540 new shares on existing shareholders.
- Confirm the net proceeds after deducting the 7.5% total fee structure (placement and management) and the $87,900 in fixed expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for covenants or restrictions.
- Check the press release (Exhibit 99.1) for the stated use of proceeds.